• ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 LIVE!™
Insights
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Client Handouts
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Coverage
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

PetDx launches new multi-cancer screening test for dogs

June 2, 2021
dvm360 Staff
dvm360, dvm360 July 2021, Volume 57,

OncoK9 offers new cancer-detection capabilities enabling veterinarians to provide the highest quality of care to their canine patients.

PetDx—a molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health—released its newest innovative product, OncoK9, a novel multi-cancer early detection test that helps veterinarians detect cancer in dogs earlier by using a simple blood draw.

“Our team at PetDx is thrilled to bring the latest scientific advances from human cancer genomics to the animal health arena. We have deployed significant efforts over the past 2 years in developing and validating OncoK9 to address a massive unmet need in the veterinary space,” says Daniel Grosu, MD, MBA, founder and CEO of PetDx, in a company release.

OncoK9 uses routine blood drawing without the need for prior fasting or sample processing. Once collected, the sample is shipped overnight at ambient temperature to PetDx’s laboratory. Upon arrival, the sample undergoes processing by using propriety methods optimized for canine cell-free DNA analysis. A digital report is then issued to the veterinarian who sent the sample, indicating if a cancer signal was detected or not.

Additionally, PetDx conducted a clinical research program in veterinary cancer diagnostics which included blood samples from nearly 1,600 client-owned dogs.1 577 of those dogs were then evaluated in the CANDiD (CANcer Detection in Dogs) study for clinical validation of OncoK9. The results showed that OncoK9 demonstrated robust clinical performance with strong cancer detection rates and very low false positives.1

“In the future, we envision offering the test for additional use cases, including minimal residual disease detection, recurrence, and treatment response monitoring, and targeted treatment selection, greatly expanding the veterinarian’s toolbox for the management of cancer in dogs,” says Andi Flory, DVM, DACVIM, Chief Medical Officer of PetDx and board-certified veterinary oncologist in the release.

PetDx recommends OncoK9 as an annual screening test for dogs that are 8 years or older and/or belong to breeds that are highly predisposed to cancer. The test is available by prescription only and serves as an aid for diagnosing dogs suspected of cancer after clinical findings or signs.

To learn more about PetDx and OncoK9, go here.

Reference

  1. Analytical and Clinical Validation of OncoK9TM, a Noninvasive Mulit-Cancer Early Detection (MCED) Test for Dogs. PetDx.com. Published 5/2021. Accessed May 26, 2021. https://petdx.bit.ai/pl/Z0ipNRsCxYUHTGKa
download issueDownload Issue: dvm360 July 2021

Related Content:

RolesTechniciansAssociatesOncologyClinicalProductsdvm360 July 2021
Earlier dermatology referral rewards primary care practice (part 1): easing client expenses and enhancing patient care
Earlier dermatology referral rewards primary care practice (part 1): easing client expenses and enhancing patient care
Further research needed in veterinary cannabis realm
Further research needed in veterinary cannabis realm
Mella Smart Thermometer approved by Fear Free for Preferred Product Program
Mella Smart Thermometer approved by Fear Free for Preferred Product Program

Latest News

Euthanasia attendants in modern practice

Earlier dermatology referral rewards primary care practice (part 1): easing client expenses and enhancing patient care

UC Davis spearheads formation of Nephrology and Urology Specialty College

One leader’s story with mental illness

View More Latest News